To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Successful Formulation of Rheumatoid Arthritis Vaccine
Read time: Less than a minute
The study results showed the "CEL-2000-DepoVax" combination considerably lessened the symptoms and slowed the progression of RA in the animal model with a single dose. The two companies will continue their research efforts to further optimize the CEL-2000-DepoVax vaccine combination for possible testing in future Phase I clinical trials.
According to the National Institutes of Health (NIH), RA is a form of arthritis that causes pain, swelling, stiffness and loss of function in the joints. The disease affects approximately 2.1 million Americans and two to three times more women than men. CEL-2000 has the potential to slow the progression of rheumatoid arthritis. The DepoVax vaccine delivery technology is amenable to manufacturing and scale up in a GMP setting, providing the potential for quicker clinical development.
"We are extremely pleased that CEL-2000, when delivered in our platform, proved efficacious with as little as one dose," said Dr. Marc Mansour, Immunovaccine's Vice President of Research and Development. "These results provide further validation of the broad potential of our DepoVax vaccine delivery technology."
The study demonstrated that the CEL-2000 formulated in DepoVax vaccine effectively slowed the progression of RA and induced a statistically significant reduction in Arthritic Index (AI) score compared to the untreated control group. An RA vaccine that provides broad protection against rheumatoid arthritis is expected to be better received than current therapies that address the symptoms associated with RA.
According to the National Institutes of Health (NIH), RA is a form of arthritis that causes pain, swelling, stiffness and loss of function in the joints. The disease affects approximately 2.1 million Americans and two to three times more women than men. CEL-2000 has the potential to slow the progression of rheumatoid arthritis. The DepoVax vaccine delivery technology is amenable to manufacturing and scale up in a GMP setting, providing the potential for quicker clinical development.
"We are extremely pleased that CEL-2000, when delivered in our platform, proved efficacious with as little as one dose," said Dr. Marc Mansour, Immunovaccine's Vice President of Research and Development. "These results provide further validation of the broad potential of our DepoVax vaccine delivery technology."
The study demonstrated that the CEL-2000 formulated in DepoVax vaccine effectively slowed the progression of RA and induced a statistically significant reduction in Arthritic Index (AI) score compared to the untreated control group. An RA vaccine that provides broad protection against rheumatoid arthritis is expected to be better received than current therapies that address the symptoms associated with RA.
